Peer-reviewedCC BY-NC-NDCirculation Journal
Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―
Abstract
BACKGROUND: The clinical consequences of discontinuing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been elucidated. METHODS AND RESULTS: We analyzed 208 patients with coronary artery disease treated with PCSK9 inhibitors. During a median follow-up of 1,096 days, 94 patients discontinued treatment and they had a higher incidence of major adverse cardiovascular events (MACE) than those who continued. Event curves diverged approximately 3 years after discontinuation. Multivariable Cox analysis showed that discontinuation was associated with a higher incidence of MACE. CONCLUSIONS: Discontinuation of PCSK9 inhibitors was associated with worse cardiovascular outcomes.
Related
- Association Between Vasopressor Discontinuation Sequence and Clinical Outcomes in Septic Shock: Norepinephrine Versus Vasopressin in the MIMIC-IV Database
- Disciform Keratitis That Improves With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitor Treatment for Ovarian Cancer but Recurs Upon Discontinuation of Treatment
- Exercise, Atherosclerosis, and Cardiovascular Outcomes: Evidence and Challenges
- Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
- Baseline Characteristics, Geriatric Syndromes, and Clinical Outcomes During Implementation of a Cardiovascular Center on Aging
BibTeX
@article{tsubata2026clinical,
title = {{Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―}},
author = {Hideo Tsubata and Naohiko Nakanishi and Noriyuki Wakana and Arito Yukawa and Norimasa Taniguchi and Hirokazu Yokoi and Kiyonari Matsuo and Natsuya Keira and Takashi Okada and Keizo Furukawa and Masahiro Koide and Satoaki Matoba and on behalf of the Kyoto PCSK9 Registry},
journal = {Circulation Journal},
year = {2026},
month = jul,
doi = {10.1253/circj.cj-26-0460},
url = {https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0460/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―
AU - Hideo Tsubata
AU - Naohiko Nakanishi
AU - Noriyuki Wakana
AU - Arito Yukawa
AU - Norimasa Taniguchi
AU - Hirokazu Yokoi
AU - Kiyonari Matsuo
AU - Natsuya Keira
AU - Takashi Okada
AU - Keizo Furukawa
AU - Masahiro Koide
AU - Satoaki Matoba
AU - on behalf of the Kyoto PCSK9 Registry
PY - 2026
DA - 2026/07/11
JO - Circulation Journal
DO - 10.1253/circj.cj-26-0460
UR - https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0460/_article
AB - BACKGROUND: The clinical consequences of discontinuing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been elucidated. METHODS AND RESULTS: We analyzed 208 patients with coronary artery disease treated with PCSK9 inhibitors. During a median follow-up of 1,096 days, 94 patients discontinued treatment and they had a higher incidence of major adverse cardiovascular events (MACE) than those who continued. Event curves diverged approximately 3 years after discontinuation. Multivariable Cox analysis showed that discontinuation was associated with a higher incidence of MACE. CONCLUSIONS: Discontinuation of PCSK9 inhibitors was associated with worse cardiovascular outcomes.
SN - 1347-4820
SN - 1346-9843
ER -